OBJECTIVE: Cardiovascular disease is strongly associated with obesity and there is evidence that weight loss has positive effects on cardiovascular disease risk. The aims of this study were to compare meal replacements (MR) with a conventional low-fat diet as weight loss strategies and to examine the effect of weight loss on flow-mediated dilatation (FMD) and other markers of endothelial function in overweight Australians with raised triglycerides (TG) (42 mmol/l). RESEARCH METHODS: Subjects matched for age, gender, fasting plasma TG and body mass index were randomized to two low-fat high-carbohydrate weight loss strategies (both o6000 kJ), one using MR and the other a structured eating plan, control (C). Subjects followed both diets for 3 months. In total, 55 subjects completed the study. FMD, pulse wave velocity and blood pressure (BP) were measured at baseline and at 3 months, as were fasting blood samples for lipids, glucose, insulin, C reactive protein (CRP) and endothelium-derived factors. RESULTS: Mean weight loss was 6.373.7 kg (6.074.2 vs 6.6373.35 kg, MR vs C) with no difference between diet groups. TG, insulin, CRP, plasminogen activator inhibitor 1 (PAI-1) and soluble intracellular adhesion molecule-1 (sICAM1) fell after weight loss, but FMD did not change. Systolic BP fell by 8 mmHg and pulse wave velocity improved. DISCUSSION: In subjects with elevated TG, weight loss resulted in significant improvements in cardiovascular risk markers, particularly endothelium-derived factors (PAI-1 and sICAM1). However, FMD did not improve with weight loss.
Introduction
Cardiovascular disease is strongly associated with obesity and there is evidence that sustained weight loss has positive effects on disease risk factors. 1 The association between obesity and hypertension is well established and its prevalence rises from 23% when body mass index (BMI) is o25 kg/m 2 to 65% when BMI is 440 kg/m 2 . 2 Hypertension is associated with progressive vascular damage and increased production of P-selectin. 3 Obesity is also associated with impaired endothelial function assessed by flow-mediated dilatation (FMD). 4 Weight loss can lower blood pressure (BP) thus improving cardiovascular disease risk. 5 Although both obesity and hypertension are associated with impaired endothelial function the evidence that weight loss improves FMD is contradictory. There is some evidence that large vessel compliance improves after weight loss 6 but the evidence available for smaller vessels is conflicting.
Improvements in endothelial function have been reported after weight loss. [7] [8] [9] [10] However, reductions in LDL cholesterol and fasting glucose concentrations but not weight loss per se were associated with improvements in FMD. [11] [12] [13] Disturbed endothelial function can also be assessed using the level of molecules secreted by the endothelium such as adhesion molecules vascular cell adhesion molecule-1 (VCAM-1), soluble intracellular adhesion molecule-1 (sI-CAM1), E-selectin, plasminogen activator inhibitor 1 (PAI-1) and tissue plasminogen activator (TPa), and there is evidence that these molecules decrease after weight loss. 14 Whether the changes seen in these molecules reflect the changes seen in endothelial nitric oxide (NO)-dependent processes such as FMD or small vessel compliance is not known. The inflammatory markers, C-reactive protein (CRP) and interleukin-6 (IL-6) fall with weight loss regardless of dietary composition 15, 16 however it is also unknown if this directly influences endothelial health although this is postulated. 17 In addition plasma homocysteine, which has a known association with cardiovascular disease and an inverse relationship with folate, has been reported to rise following surgery for weight loss but whether this alters endothelial function is not known. 18, 19 The first aim of the study was to compare weight loss using either meal replacements (MR) or a conventional low-fat high-carbohydrate diet. These data have already been reported. 20 The second aim was to examine the effects of weight loss on a wide variety of cardiovascular risk markers, but in particular FMD. We hypothesized that weight loss would reverse impaired vascular physiology by improving FMD and markers of inflammation and endothelial function.
Methods
Design, subjects and screening In total, 300 overweight and obese subjects (BMI 27-40 kg/m 2 ) subjects were screened for fasting TG42 mmol/l. Of them, 66 subjects were selected and matched for age, gender, fasting plasma TG and BMI and randomized to two low-fat high-carbohydrate weight loss strategiesFone using MR and the other using a structured eating plan control (C). There were no differences between MR and C for age, TG and BMI at baseline (Table 1 ). In total, 55 subjects completed the study (11 dropouts, seven MR, two lost to follow-up, one did not like the products, two because of unrelated medical conditions, two changes in personal circumstances and four C, two lost to follow-up, one pregnancy, one bereavement). The study was approved by the Ethics Committee of the CSIRO Division of Health Sciences and Nutrition, and subjects were informed of procedures and signed a consent form prior to commencement.
Dietary intervention
Each dietary treatment, MR and C, was restricted to 6000 kJ/day (about two-thirds of normal intake) for a planned weight loss of 6-12 kg. MR were advised to consume two meal replacements as Slimfastt (1800 kJ), a low-fat evening meal per day and at least five serves of fruit and vegetables/ day (3500 kJ) as outlined in the Slimfastt literature. Slimfast product was provided at 2-week intervals. Subjects randomized to C were advised to follow a structured low-fat highcarbohydrate diet. Financial compensation equivalent to the cost of the Slimfastt meals was provided every 2 weeks to C as a shopping voucher to the value of $A50. Subjects in both groups were weighed every 2 weeks, but were not provided with subsequent dietary advice. A 300 mg nitro-glycerine (GTN) tablet, an endothelium-independent dilator, was then administered under the tongue. Measurements were recorded for 4 min at 15 s intervals. Anterior to posterior medial diameters were measured off-line for all images, at end diastole as deduced by the ECG. Endothelium-dependent and -independent dilatations were expressed as percentage change relative to the average baseline diameter. The coefficient of variation for this technique was 10% (n ¼ 6).
Pulse wave velocity
Using a Doppler probe, aortic PWV was measured via sequential recordings of arterial sound waves produced at the carotid (CA) and (FA). Approximately 10 consecutive beats were recorded. A simultaneous ECG recording was used to calculate the time between the R-wave and the upstroke of each sound wave. The difference between the average pulse time delays for the arteries was calculated (PT, seconds). PWV was then determined by dividing the measured distance between CA and FA (using a tape measure, meters), by pulse time.
Laboratory analysis
Fasting blood samples were taken at weeks 0 and 12 for lipids, glucose, insulin, clotting and vascular markers, CRP, VCAM1, sICAM1, PAI-1, tPa and IL-6. Blood samples were collected into 4 ml tubes containing Na 2 EDTA (final concentration 1 g EDTA/l), for measurement of plasma sICAM-1 and VCAM-1 concentrations, and into 8 ml tubes without Na 2 EDTA, for measurement of serum total cholesterol (TC), TG, HDL-C and CRP concentrations. 
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Plasma samples were isolated by the Beckman GS-6 Series centrifugation at 2500 rpm for 10 min. Serum samples were isolated by centrifugation at 3000 r.p.m for 10 min. Aliquots were frozen at À801C until study completion. Plasma glucose and serum TC and TG concentrations were measured with a Cobas-Bio centrifugal analyzer (Roche Diagnostica, Basel, Switzerland) using enzymatic kits (Hoffmann-La Roche Diagnostica, Basel, Switzerland) and control sera. Plasma HDL-cholesterol (HDL-C) concentrations were measured using a Cobas-Bio centrifugal analyzer after precipitation of LDL-cholesterol (LDL-C) and VLDLcholesterol with polyethylene glycol 6000 solution. LDL-C concentrations in serum were calculated using a modified version of the Friedwald formula. 22 The following tests were performed by ELISA: Coaliza s t-Pa and PAI-1 (Chromogenix, Sweden), sVCAM1 and ICAM1 (Immunokontact), CRP (Alpha Diagnostic International, Texas) and IL-6 (Sapphire Bioscience, Sydney, Australia).
Insulin was determined in duplicate using a radioimmunoassay kit (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). Plasma folate and homocysteine were measured in a certified commercial laboratory.
Statistical analysis
Repeated measures analysis of variance was calculated with treatment period as the within-subject factor and with diet as the between-subject factor. Age, baseline TG, BMI and change in weight between periods were inserted into the model as covariates where appropriate. Analyses were performed with SPSS 11.5 for WINDOWS (SPSS Inc., Chicago, USA).
Power estimate
We had enough power (80%, a 0.05) to detect a difference between diets of 2 kg in weight, a difference in fasting insulin of 3 mIU/l and a difference in LDL-C of 0.2 mmol/l.
Data are presented as means7s.d. unless otherwise stated. Aspects of this study, including weight loss, details of dietary methodology and nutritional intakes, are reported elsewhere. 20 
Results

Weight
There was a highly significant weight loss (Po0.001) after 3 months of (6.074.2 vs 6.6373.35 kg, MR vs C) mean 6.373.7 kg with no differences between the diet groups.
Since there was no difference in weight loss between the groups, results for all other variables were analyzed with the whole study sample. Figure 1 .
FMD, PWV and BP
Baseline BMI and baseline FMD or changes in FMD were not correlated. Change in weight and FMD were not correlated.
PWV
In the whole group PWV improved after weight loss from 7.4672.86 to 6.2871.46 m/s (Po0.05) ( Table 2 ). Table 2) . PWV and systolic BP were correlated before (r, 0.30, Po0.01) and after weight loss (r, 0.45, Po0.01). However, there was no correlation between the change in PWV and change in BP after weight loss (r, 0.05, P ¼ NS).
Lipids, glucose and insulin TG fell after weight loss in the C group only (Po0.01). There were no net changes in TC, LDL C or HDL-C after weight loss (Table 3) .
Glucose did not change but insulin fell after weight loss with no difference between the diets by B29% (Po0.001) ( Table 3 ).
Folate and homocysteine
Neither folate nor homocysteine changed after weight loss (Table 3) .
CRP and endothelium-derived factors CRP remained unchanged after weight loss (5.7575.87 vs 6.1779.28 mg/l). However, when those with CRP410 mg/l at either time point were excluded from the analysis there was a significant reduction in CRP (3.6572.15 vs 3.0172.19, Po0.01) with no effect of diet (Table 4) .
tPA fell by 7% (Po0.05) and PAI-1 by 17% (Po0.01) ( Table 4) . sICAM1 fell by 8% (Po0.001). No changes in sVCAM1 or IL-6 were noted (Table 4) .
Discussion
The main finding of this study was that in overweight subjects with elevated TG, FMD did not change despite weight loss of B6 kg on either of two low-fat highcarbohydrate diets. However, weight loss was associated with improvements in other measures of vascular health, namely PWV and BP. There were also positive changes in endothelium-derived factors , PAI-1 and sICAM1, CRP, insulin and TGs. reported improvements in endothelium-dependent vasodilatation in an orlistat treated group following similar weight loss on either orlistat or placebo. A reduction in LDL-C, seen in the orlistat group only, but not weight loss per se, correlated with the improvements in blood flow. We did not observe reductions in LDL-C despite a low-fat intake of B20% energy from fat. Similar, to our study, Brook et al 12 did
FMD PWV and BP
not demonstrate improvement in FMD following weight loss with reduction in LDL cholesterol using orlistat. Raitakari et al 13 report improvements in FMD after weight loss on a very low calorie, low carbohydrate (70 g/day) diet, which correlated with reductions in fasting glucose concentrations but not with the reduction in LDL-C or weight loss. The subjects in our study had a higher energy and carbohydrate intake (B 6000 kJ, 22% fat, 455% carbohydrate, 4170 g carbohydrate) and we did not find reductions in either fasting glucose or LDL-C or concentrations. Hamdy et al 10 observed improved FMD following weight loss (B7 kg) on an energy restricted diet and moderate intensity exercise program (60-80% maximal heart rate) with no changes in either LDL-C or fasting glucose. Central adiposity is associated with reduced FMD 5, 22 and weight loss has been shown to also reduce abdominal fat. 26 However, studies of weight loss and FMD have not measured body fat distribution and this requires investigation. Whether dietary macronutrient composition affects endothelial function is also controversial. In Bergholm's study weight loss of 7 kg was achieved using a moderate fat (30% of energy), highcarbohydrate diet, (50% of energy) with or without orlistat.
11
Improved endothelial function in the orlistat-treated group correlated with reductions in LDL-C Whereas in Brook's study subjects lost similar amounts of weight on an energy restricted diet with 30% energy as fat, LDL-C fell without an effect on FMD. We have observed impairment of FMD in response to a high saturated fat diet compared to high monounsaturated fat, high polyunsaturated fat or low-fat diets in weight stable subjects. 27 The effects of weight loss, dietary composition and other end points that may be affected by diet, on FMD need to be clarified in future studies. Aortic PWV is used as an indirect measure of aortic stiffness with a faster PWV indicating a stiffer aorta, and aortic stiffness is an independent predictor of mortality in hypertensive patients. 28 Sutton-Tyrrell et al 29 CRP, IL-6, tPA, PAI-1, sICAM-1 and sVCAM-1 In the present study, CRP decreased but IL-6 did not change. Reductions in tPA, PAI-1 and sICAM1 were also observed but no change in sVCAM1 was noted. Fat cells produce cytokines, in particular IL-6, which induces the synthesis of CRP by the liver. CRP levels in blood are a good indicator of the likelihood of acute coronary and cerebral events in both healthy subjects and patients with coronary artery disease. 16, 36 CRP is positively associated with BMI and we and others have shown that energy striction and weight loss lowers CRP. 16 observed reduction in IL-6 after weight loss. Levels of ICAM-1, predict future cardiovascular events in healthy subjects and reduction of these markers leads to a reduction in cardiovascular disease risk. 40 However, the effect of weight loss on these molecules needs further clarification. Interpretation of the long-term impact of the reductions in tPa and PAI-1 levels with weight loss is not clear. PAI-1
Endothelial function and weight loss PM Clifton et al appears to be an independent predictor of myocardial infarction at least in elderly subjects, 41 while tPa is also an independent predictor 42 with a risk ratio of 5.9 between quartiles for first myocardial infarction.
Homocysteine and folate
Neither folate nor homocysteine changed after weight loss. Similarly, Volek et al 43 did not observe changes in homocysteine after 4 kg of weight loss on a reduced fat diet, with vitamin/mineral supplements including folic acid. Similarly, Fleming 44 in a study of 100 men and women, found no significant effect of weight loss in homocysteine. In crosssectional studies, folate was found to have a greater effect on endothelial function than homocysteine. 45 In conclusion, in this study of subjects with elevated TGs, weight loss on either of too low-fat high-carbohydrate diets was associated with improvements in cardiovascular risk factors and markers of vascular function but did not improve FMD. Further studies are needed to clarify the conflicting results observed using these outcome variables.
